...
首页> 外文期刊>Journal of the American Society of Nephrology: JASN >Angiotensin-converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn-hooded rat.
【24h】

Angiotensin-converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn-hooded rat.

机译:血管紧张素转换酶抑制在预防和治疗高血压小鹿罩大鼠的慢性肾脏损伤中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The spontaneously hypertensive fawn-hooded rat (FHH) develops accelerated albuminuria and focal glomerular sclerosis (FGS), leading to ESRD and shortening of lifespan. The FHH is characterized by moderate systemic hypertension, a relatively low afferent to efferent arteriolar resistance ratio, and glomerular hypertension. The FHH study presented here was designed to examine the efficacy of early-onset, late-onset, or early-temporary angiotensin I-converting enzyme inhibition (ACE-i) in ameliorating long-term hypertension and FGS, and improving survival, as well as to relate its protective efficacy to preexistent FGS and to reduction of glomerular pressure (PGC) Untreated rats developed hypertension and high PGC, and all (N = 22) except one died of ESRD within the 72-wk follow-up period. Early-onset (at 7 wk of age) ACE-i prevented development of systemic and glomerular hypertension, and it largely prevented proteinuria and FGS; all rats survived throughout the follow-up period. Rats treated with late-onset (22 wk) ACE-i were hypertensive and proteinuric at the start of ACE-i, and they showed beginning FGS. ACE-i corrected the hypertension, albuminuria, and PGC but could not fully prevent some hypertension, albuminuria, and FGS at the later stage. Early-temporary (7 to 22 wk) ACE-i adequately controlled blood pressure and development of FGS during therapy, but after withdrawal of ACE-i, systemic and glomerular hypertension developed as in untreated animals. This regimen postponed but did not control FGS development and early mortality. The results of this study indicate that: (1) early-onset ACE-i very effectively protects against development of renal damage in the FHH; (2) this protection is associated with normalization of the elevated glomerular capillary pressure; (3) ACE-i cannot completely prevent further development of previously established FGS, despite lowering glomerular capillary pressure; (4) early-temporary ACE-i has no long-term controlling effect on arterial and glomerular pressure, andit cannot control development of FGS.
机译:自发性高血压小鹿型大鼠(FHH)会加速蛋白尿和局灶性肾小球硬化(FGS),导致ESRD和寿命缩短。 FHH的特征是中度全身性高血压,相对较低的传入和传出小动脉阻力比率以及肾小球高血压。本文介绍的FHH研究旨在检查早期发作,晚期发作或早期临时血管紧张素I转化酶抑制(ACE-i)在改善长期高血压和FGS以及改善生存率方面的功效关于其对先前存在的FGS的保护作用和与降低肾小球压力(PGC)的关系未经治疗的大鼠发展为高血压和高PGC,除72例随访期内,全部(N = 22)除一只死于ESRD。 ACE-i较早发作(7周龄)可预防全身性和肾小球性高血压的发展,并在很大程度上预防蛋白尿和FGS。所有大鼠在整个随访期间均存活。迟发性(22周)ACE-i治疗的大鼠在ACE-i开始时具有高血压和蛋白尿作用,并且表现出开始的FGS。 ACE-i纠正了高血压,白蛋白尿和PGC,但在后期无法完全预防某些高血压,白蛋白尿和FGS。早期(7至22周)ACE-i在治疗期间可充分控制血压和FGS的发展,但撤回ACE-i后,全身性和肾小球性高血压的形成与未经治疗的动物相同。该方案推迟但不能控制FGS的发展和早期死亡率。这项研究的结果表明:(1)早发ACE-i非常有效地保护了FHH免受肾脏损害的发展; (2)这种保护作用与肾小球毛细血管压升高的正常化有关; (3)尽管降低了肾小球毛细血管压力,ACE-i仍不能完全阻止先前建立的FGS的进一步发展; (4)早期ACE-i对动脉和肾小球压力无长期控制作用,不能控制FGS的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号